Abstract: OBJECTIVE To explore the clinical supplementary role of Shenqi Fuzheng Injection in treating digestive tract tumor during chemotherapy and its resistance to the side effects induced by chemotherapy. METHODS 156 cases with digestive tract tumor hospitalized in our hospital from 2014 to 2016 were collected and randomly divided into the combined chemotherapy group and control group， with 78 cases in each group. The conventional chemotherapy regimen was designed to the control group， while patients in the treatment group were further given 250mL/d of Shenqi Fuzheng Injection. Then chemotherapeutic effects were assessed after chemotherapy to evaluate the chemotherapy efficiency rate and disease control rates(DCR). To be specific， the activities of CD3⁺， CD4⁺， CD8⁺， CD4⁺/CD8⁺ and NK cells as well as the peripheral blood cell level before and after treatment were tested to record and count the side effects appearing during chemotherapy. RESULTS There existed statistical differences between the combined chemotherapy group and control group in efficiency distribution after chemotherapy(P<0.05). The blood cell level of both groups went down after chemotherapy. The immune cell activity of the control group went down， while that of the combined chemotherapy group went up. And the levels of CD3⁺， CD4⁺， CD8⁺， CD4⁺ /CD8⁺， NK and diverse blood cells of the combined chemotherapy group were higher then those of the control group(P<0.05); The appearance rate of the side effects in the combined chemotherapy group was 74.35%， lower than 88.46% of the control group(P<0.05). CONCLUSION Shenqi Fuzheng Injection has certain effects on the improvement of chemotherapy efficiency for patients with digestive tract tumor， and also change the hypoimmunity and side effects induced by chemotherapy.